Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

(h)MeDIP-Seq of high-risk prostate cancer

ABSTRACT: Immunoprecipitation of methylated and hydroxymethylated DNA was performed on DNA isolated from tumoral and non-tumoral prostate tissue of patients with high-risk disease. Samples were sequenced on the Illumina HiSeq as 50 bp single end.

PROVIDER: EGAS00001001019 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Publications

Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1.

Spans Lien L Van den Broeck Thomas T Smeets Elien E Prekovic Stefan S Thienpont Bernard B Lambrechts Diether D Karnes R Jeffrey RJ Erho Nicholas N Alshalalfa Mohammed M Davicioni Elai E Helsen Christine C Gevaert Thomas T Tosco Lorenzo L Haustermans Karin K Lerut Evelyne E Joniau Steven S Claessens Frank F

Oncotarget 20160401 17

The clinical heterogeneity of prostate cancer (PCa) makes it difficult to identify those patients that could benefit from more aggressive treatments. As a contribution to a better understanding of the genomic changes in the primary tumor that are associated with the development of high-risk disease, we performed exome sequencing and copy number determination of a clinically homogeneous cohort of 47 high-risk PCas. We confirmed recurrent mutations in SPOP, PTEN and TP53 among the 850 point mutati ...[more]

PMID: 27014907

Similar Datasets

Exomes of High-risk Prostate cancer

Project description:DNA extracted from tumoral tissue of 39 patients was used for exome sequencing. As a comparison, DNA extracted from blood was used as a non-tumoral control. DNA was captured using the EZ SeqCap v3 exome kit from Roche and sequenced using an Illumina HiSeq instrument.

| EGAS00001001015 | EGA

Epigenomic alterations in localized and advanced prostate cancer

Project description:Here we used Illumina NGS for high-throughput profiling of the DNA methylome in seven human benign prostate tissues, seven human primary prostate cancer and six human castration resistant prostate cancer patient samples. These data were used to profile the CpG cytosine methylation pattern at single base resolution in each sample and to determine differentially methylated cytosines and regions among samples. Enhanced Reduced Representation Bisulfite Sequencing (ERRBS, MspI,150M-bM-^@M-^S400 bp size fractions) of 20 human prostate tissues (benign prostate tissues, localized and metastatic prostate cancer)

2013-07-03 | E-GEOD-41701 | biostudies-arrayexpress

ena-DATASET-IBT-12-06-2013-16:46:58:065-20 - samples

Project description:Methylated DNA immunoprecipitation sequencing of 28 untreated prostate cancers, 11 castration resistant prostate cancers, and 12 benign prostatic hyperplasias.

| EGAD00001000610 | EGA

MeDIP

Project description:A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis

| PRJEB2021 | ENA

Deciphering Epigenetic Regulation of Enhancers in High-Risk Prostate Cancer

Project description:Prostate cancer (PCa) is associated with widespread promoter hypermethylation. We hypothesized that aberrant DNA methylation also targets gene enhancers, modulating their activity and contributing to disease etiology. DNA methylation was assessed in a discovery set (n = 37) of primary PCa via the Infinium methylation EPIC array, using high-risk (HR; n=13), low-risk (LR; n=11), and histologically benign (n=13) tissues. A higher proportion of enhancers was hypomethylated in HR (n=385, 15%) than LR (n=105, 10%) PCa, primarily targeting genes involved in development and enriched for oncoprotein binding motifs, including FOXA1. Clinical significance was evaluated by identifying a 17 enhancer differentially methylated probe (DMP) signature using a Least Absolute Shrinkage and Selection Operator model in the discovery set. A logistic regression model was trained using the HR PCa-specific signature in a training set (n=490) and validated in a testing set (n=256). The signature had a 0.81 (95% bootstrapped CI 0.78-0.9) area under the curve, for selective detection of HR PCa, achieving a 0.71 sensitivity and 0.76 specificity (testing set). Array-wide aberrant DNA methylation at enhancers highlighted their epigenetic perturbance in HR disease. A clinically significant enhancer signature from this study could be used for detecting HR PCa.

2025-05-09 | GSE245609 | GEO

MeDIP-seq in human lung cancer tissues

Project description:we used methylated DNA immunoprecipitation sequencing (MeDIP-Seq) to detect DNA methylation levels and lncRNA-seq to detect lncRNA expression levels in 3 lung cancer samples and 3 matched normal samples. Then 255 differentially methylated genes (DMGs) and 246 differentially expressed lncRNAs (DELs) were identified. Finally, LINC01354 was founded to be differentially methylated and predictive of transcription. Besides, the prognostic value of differential methylation related DELs was analyzed.

2023-03-01 | GSE226271 | GEO

MeDIP for ten early passage melanoma cell cultures

Project description:Malignant melanoma is the most fatal skin cancer with a high degree of genetic and epigenetic aberrations. To investigate the role of DNA methylation on melanoma heterogeneity, we performed methylated DNA immunoprecipitation (MeDIP) microarray analysis of 10 primary melanoma cell cultures. methylated DNA immunoprecipitation (MeDIP) microarray analysis of 10 primary melanoma cell cultures

2014-05-28 | E-GEOD-57971 | biostudies-arrayexpress

The cell free DNA methylome of primary and metastatic prostate tumors

Project description:Metastatic prostate cancer remains a major clinical challenge. Liquid biopsy is emerging as a promising tool in disease management and provides valuable opportunities to gain insights into the underlying biology. Here, we used the highly sensitive, methylated DNA immunoprecipitation coupled to next generation sequencing (MeDIP) technology, to interrogate the cell-free DNA methylomes across localized and metastatic prostate cancer.

| EGAS00001005522 | EGA

MeDIP sequencing for human samples

Project description:We report a high-throughput analysis of human breast cancer cells using methylated DNA immunoprecipitation-sequencing.in this study to reveal the difference in methylation between breast cancer drug-resistant cells and sensitive cells. A total of 55076 differentially methylated genes (DMGs) were detected, including 21061 hypermethylated DMGs and 34015 hypomethylated DMGs. Moreover, Gene Ontology (GO) analysis and KEGG pathway analysis reveal the function and pathway of screening genes. These results indicate that DNA methylation may be involved in regulating the occurrence and development of breast cancer.

2020-08-01 | GSE155485 | GEO

Stella regulates the development of female germline stem cells by modulating chromatin structure and DNA methylation [MeDIP-seq]

Project description:Genome-wide DNA methylation was assessed by methylated DNA immunoprecipitation

2022-05-25 | GSE189427 | GEO